MIM
PGNX

MetLife Investment Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

MetLife Investment Management’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-12,569
Closed -$47.8K – 2398
2020
Q1 		$47.8K Sell
12,569
-29,130
-70% -$126K ﹤0.01% 2229
2019
Q4 		$212K Hold
41,699
– – ﹤0.01% 1948
2019
Q3 		$211K Hold
41,699
– – ﹤0.01% 1915
2019
Q2 		$257K Buy
41,699
+9,436
+29% +$45.5K ﹤0.01% 1884
2019
Q1 		$150K Hold
32,263
– – ﹤0.01% 2144
2018
Q4 		$136K Hold
32,263
– – ﹤0.01% 2134
2018
Q3 		$202K Hold
32,263
– – ﹤0.01% 2071
2018
Q2 		$259K Hold
32,263
– – ﹤0.01% 1791
2018
Q1 		$241K Hold
32,263
– – ﹤0.01% 1789
2017
Q4 		$192K Buy
+32,263
New +$196K ﹤0.01% 1952

Other funds holding PGNX

ECM
Everence Capital Management Goshen, Indiana $1.9B AUM 39.77% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
Daiwa Securities Group
Daiwa Securities Group Tokyo, Japan $51.1B AUM 35.55% 1-Year Est. Return

MetLife Investment Management's PGNX Position: Q2 2020 in Review

MetLife Investment Management sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 12,569 shares — an estimated $47.8K sold.

MetLife Investment Management first reported a position in PGNX in Q4 2017 and held it in 10 quarters. The position peaked at $259K in Q2 2018. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.

  • MetLife Investment Management reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
  • MetLife Investment Management sold 12,569 Progenics Pharmaceuticals Inc shares in Q2 2020, an estimated $47.8K.
  • MetLife Investment Management first reported a position in Progenics Pharmaceuticals Inc in Q4 2017 and held it in 10 quarters.
  • MetLife Investment Management's Progenics Pharmaceuticals Inc position peaked at $259K in Q2 2018.
  • 3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.

Based on MetLife Investment Management's 13F filing for Q2 2020, filed 14 Aug 2020.